4151 (4151) News
Follow 4151 (4151) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 6 public stories across 4 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Kyowa Kirin Co., Ltd. Grants Knight Exclusive LATAM Rights for Mogamulizumab
Kyowa Kirin signed an exclusive distribution agreement with Knight Therapeutics for mogamulizumab in Argentina, Brazil, Colombia and Mexico. Knight will seek regulatory approvals and commercialize the drug for MF and Séz
NEWS | Sep 29, 2026, 12:00 PM UTC
L
Kyowa Kirin and Knight Therapeutics Enter Into Exclusive Distribution Agreement for POTELIGEO® (mogamulizumab) for Cutaneous T-Cell Lymphoma (CTCL) Patients Across Latin America
Kyowa Kirin International, a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin), today announced the signing of an exclusive distribution agreement with Knight Therapeutics (“Knight”) (TSX:GUD) for
NEWS | Sep 29, 2026, 12:00 PM UTC
L
KHK4951 eye drops maintained vision in most nAMD patients at 52 weeks
KHK4951 eye drops maintained vision in 65-69% of Phase 2 patients with nAMD without rescue injections at 52 weeks, with stable safety and tolerability, per the source.
EQUITY | Sep 09, 2026, 07:41 AM UTC
M
Jefferies flags disappointing Phase 2 eye-drop results for KHK4951
Jefferies says Kyowa Kirin’s latest Phase 2 clinical data for ophthalmology eye drops candidate KHK4951 is disappointing, materially weakening a key pipeline opportunity.
EQUITY | Sep 09, 2026, 02:58 AM UTC
M
Kyowa Kirin signs US voluntary agreement to lower US medicine costs
Kyowa Kirin announced a voluntary agreement with the U.S. government to improve access and lower the cost of medicines for American patients.
EQUITY | Sep 01, 2026, 08:28 AM UTC
L
Kyowa Kirin agrees with US administration to reduce treatment costs
Kyowa Kirin announced an agreement with the US administration aimed at reducing treatment costs for Americans.
EQUITY | Aug 31, 2026, 08:09 PM UTC